Document is current
Any future updates will be listed below
-
Authors
Faraji, Farhoud https://orcid.org/0000-0001-5078-813X
Ramirez, Sydney I. https://orcid.org/0000-0002-7166-5195
Clubb, Lauren M.
Sato, Kuniaki https://orcid.org/0000-0001-6014-1911
Burghi, Valeria
Hoang, Thomas S.
Officer, Adam
Anguiano Quiroz, Paola Y.
Galloway, William M. G.
Mikulski, Zbigniew
Medetgul-Ernar, Kate
Marangoni, Pauline
Jones, Kyle B.
Cao, Yuwei
Molinolo, Alfredo A.
Kim, Kenneth https://orcid.org/0000-0002-5993-4575
Sakaguchi, Kanako
Califano, Joseph A. III
Smith, Quinton https://orcid.org/0000-0001-7079-1176
Goren, Alon
Klein, Ophir D. https://orcid.org/0000-0002-6254-7082
Tamayo, Pablo
Gutkind, J. Silvio https://orcid.org/0000-0002-5150-4482
- License Information
-
More Information
Article History
Received: 24 August 2024
Accepted: 18 December 2024
First Online: 8 January 2025
Competing interests
: J.S.G. has received other commercial research support from Kura Oncology, Mavupharma, Dracen, Verastem, and SpringWorks Therapeutics, and is a consultant/advisory board member for Domain Therapeutics, Pangea Therapeutics, and io9, and founder of Kadima Pharmaceuticals. The remaining authors declare no competing interests.
